Milestone Pharmaceuticals’ CARDAMYST: A Promising Buy with FDA Decision and Phase 3 Trial on Horizon
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals (MIST – Research ...
Strategic Positioning and Financial Outlook: Ritu Baral’s Buy Rating on Milestone Pharmaceuticals Amidst Etripamil’s Promising Market Launch
TD Cowen analyst Ritu Baral maintained a Buy rating on Milestone Pharmaceuticals (MIST – Research Report) yesterday and set a price ...
Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided ...
National Institute for Health and Care Excellence23d
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria
There is a simple discount patient access scheme for danicopan. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...